Fig. 1 | British Journal of Cancer

Fig. 1

From: A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas

Fig. 1The alternative text for this image may have been generated using AI.

Mean ± SEM plasma concentration–time profiles (semi-log) of TSR-011 following single oral daily doses in patients with cancer. a Cycle 1/day 1. b Cycle 2/day 1. Summary of ΔQTcF by plasma concentration and dose. c PK concentration–response (PK-QT) relationship from all dose groups (30 mg QD, 60 mg QD, 80 mg QD, 120 mg QD, 240 mg QD, 320 mg QD, 480 mg QD, 30 mg Q12h, 20 mg Q8h, 60 mg Q12h, 40 mg Q8h and 30 mg QD controlled release). d Plot of dose and regimen versus mean ΔQTcF (ms) from baseline with 90% CI. ΔQTcF change in Fridericia-corrected QT interval, CI confidence interval, Conc concentration, IR immediate release, PK pharmacokinetics, Q8h once every 8 hours, Q12h once every 12 hours, QD once daily, SEM standard error of the mean

Back to article page